Gilead Q1 2026 Earnings: Strong Esthugo Growth Drives HIV Business
Gilead Sciences (GILD) announced its Q1 2026 earnings, driven by strong sequential growth of 72% in Esthugo sales for HIV prevention. The company also emphasized its robust pipeline with no major patent expirations until 2036.
Key Numbers
Gilead Sciences (GILD) reported its Q1 2026 financial results, highlighting strong performance driven by the successful launch of Esthugo in HIV prevention. The company did not disclose specific revenue or net income figures in the summary but focused on the accelerating growth of Esthugo.
Key Financial Results
| Metric | Q1 2026 | Change |
|---|---|---|
| Esthugo sales growth | 72% | Sequential |
| Total revenue | Not disclosed | - |
| Net income | Not disclosed | - |
| EPS | Not disclosed | - |
Key Highlights
Gilead stated that the success of the Esthugo launch is the key driver of growth in HIV prevention. The company also noted that its HIV business is poised for strong, durable growth, supported by up to seven potential new HIV product launches by 2033.
Guidance
Gilead did not provide specific numerical guidance for the next quarter but reiterated that there are no major loss of exclusivity (LOE) events until 2036, providing a long runway for growth.
Stock Impact
The stock reaction was not mentioned, but the focus on Esthugo growth and pipeline strength likely supports investor confidence in the company's long-term prospects.
What This Means for Investors
Q1 results indicate that Gilead is making progress in diversifying its revenue beyond older drugs. With no major LOEs until 2036, the company has a solid foundation for growth. However, investors should monitor competition in the HIV market and new drug launches.
Frequently Asked Questions
Found this useful? Share it